Celularity, Inc. (NASDAQ:CELU) Short Interest Down 23.2% in April

Celularity, Inc. (NASDAQ:CELU) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totaling 226,425 shares, a decrease of 23.2% from the March 31st total of 294,642 shares. Based on an average daily volume of 15,910 shares, the short-interest ratio is currently 14.2 days. Approximately 0.9% of the shares of the company are short sold.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CELU. Acadian Asset Management LLC bought a new position in shares of Celularity in the first quarter valued at approximately $34,000. XTX Topco Ltd boosted its holdings in shares of Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after acquiring an additional 11,057 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after acquiring an additional 35,023 shares in the last quarter. HB Wealth Management LLC bought a new position in Celularity during the third quarter valued at about $84,000. Finally, Vanguard Group Inc. boosted its stake in Celularity by 35.3% during the third quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after buying an additional 176,518 shares in the last quarter. 19.02% of the stock is currently owned by institutional investors.

Celularity Stock Performance

Shares of NASDAQ:CELU traded up $0.01 on Thursday, hitting $0.97. The company’s stock had a trading volume of 53,924 shares, compared to its average volume of 126,251. Celularity has a 12 month low of $0.94 and a 12 month high of $4.35. The company has a market capitalization of $27.97 million, a price-to-earnings ratio of -0.29 and a beta of 0.70. The stock’s 50-day moving average is $1.25 and its two-hundred day moving average is $1.46.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.